AEterna Zentaris Inc. (AEZS)

[chmcnfunds]

Took a look at Dodd's conference call (quick but not intense look). A few statement stand out:

"Good morning and thank you for joining us. This is an exciting time for Aeterna Zentaris. We are approaching a major inflection point for our company as we expect to complete two pivotal Phase 3 studies during the coming months and report top-line results for the Macrilen confirmatory study prior to yearend.

Regarding Zoptrex, we expect to report top-line results in the first quarter 2017. I will say more about this later, but let me first provide a brief summary of our achievements during the second quarter.'

No imminent data unless a halt.

"We ended the quarter with unrestricted cash and cash equivalents of approximately $26.2 million, however, our cash and cash equivalent at the end of June will not be sufficient to fund our operation for the 12-month period following such date. And as a result, our second quarter financial statement, contained a footnote, disclosing material uncertainties related to events and conditions that may cast substantial doubts about our ability to continue as a going concern for at least one year from June 30, 2016. We expect to address the situation before the end of the year." NOTE, they usually have $45-$50M. Going to be an offering.

Sure don't see any reason to rush in unless big drop and becomes badly oversold. Currently over-bought on CCI and Wm%(14):




(I have no shares)

AEZS